Ignite Creation Date:
2024-05-06 @ 9:00 AM
Last Modification Date:
2024-10-26 @ 12:08 PM
Study NCT ID:
NCT02871791
Status:
COMPLETED
Last Update Posted:
2022-08-29
First Post:
2016-06-29
Brief Title:
Palbociclib With Everolimus Exemestane In BC
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
16-177
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Dana-Farber Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Sara Tolaney
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Pfizer | INDUSTRY |